XLRN - Acceleron Pharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Acceleron Pharma's activity chart (see below) currently has 196 price targets and 142 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 84.31% with an average time for these price targets to be met of 192.24 days.

Most recent stock forecast was given by from JEFFERIES on 08-Oct-2021.

Best performing analysts who are covering XLRN - Acceleron Pharma:

Yaron Werber Danielle Brill Yigal Nochomovitz Edward White Geoffrey Porges

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 06-Oct-2021

$180

4 years 11 months 4 days ago
(08-Oct-2021)

0/3 (0%)

$4.71 (2.69%)

Buy Since 16-Nov-2018

$180

4 years 11 months 7 days ago
(05-Oct-2021)

16/17 (94.12%)

$7.9 (4.59%)

257

Buy Since 25-Feb-2019

$180

4 years 11 months 10 days ago
(02-Oct-2021)

7/8 (87.5%)

$5.65 (3.24%)

185

Buy Since 10-Jul-2018

$180

$1.25 (0.70%)

$180

4 years 11 months 10 days ago
(02-Oct-2021)

7/9 (77.78%)

$5.65 (3.24%)

307

Buy Since 03-Feb-2020

$180

4 years 11 months 10 days ago
(02-Oct-2021)

7/8 (87.5%)

$7.9 (4.59%)

100

Show more analysts

Please expand the browser size to see the chart

What is XLRN (Acceleron Pharma) average time for price targets to be met?

On average it took 192 days for the stock forecasts to be reached, with an average price target met ratio of 84.31%.

Which analyst most recently updated their price target on XLRN (Acceleron Pharma)?

Which analyst has the most public recommendations on XLRN (Acceleron Pharma)?

has 0 price targets and 0 ratings on XLRN

Which analyst is the currently most bullish on XLRN (Acceleron Pharma)?

Edward Tenthoff with the highest potential upside of $1.25

Which analyst is the currently most reserved on XLRN (Acceleron Pharma)?

Geoff Meacham with the lowest potential downside of -$133.75

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?